Mindray Medical, a $3.5 billion Shenzhen medical device company, may be taken private, according to unconfirmed press reports; iKang Healthcare acquired a 70% stake in WA Centers HK Limited, which owns two high-end medical centers in China; Denovo Biopharma, a US-China startup, obtained global rights to a late-stage neuroscience drug from Eli Lilly; Leica Biosystems of Germany gained exclusive rights to distribute Novacyt’s cervical cancer test in Greater China; we published an interview with Michael Yu, CEO of Innovent, a China biosimilar company that raised $100 million in January; Hutchison Chi-Med plans to file two New Drug applications for innovative cancer drugs in 2016; China Wanbang Biopharma successfully completed the toxicology study of a novel treatment for type 2 diabetes: China formally established the Biosimilar Approval process that was issued in draft form last fall; and China's State Council decreed that China hospitals must purchase drugs only from provincial pharmaceutical procurement platforms.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
